Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Stephen (Steve) H. Rusckowski, former chairman, president and chief executive officer of Quest Diagnostics, Inc., to its board of directors. Effective today, Mr. Rusckowski serves on Baxter’s Compensation and Human Capital, and Quality, Compliance and Technology Committees. In addition, the company has announced that Michael (Mike) Mahoney will be resigning from the board effective Sept. 13, 2023, following nearly eight years of service.
“We are pleased to welcome Steve to Baxter’s board,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “His exemplary operational expertise, track record as a transformational leader, and distinguished career as a strategic operational executive will enhance our current board membership. I’m confident Steve’s patient-centric approach will further advance our Mission to Save and Sustain Lives.”
Added Almeida, “I also want to thank Mike for his many contributions to the Baxter board over his eight-year tenure. His extensive insight into the medical device industry and deep leadership experience have helped guide Baxter’s ongoing transformation, including our current strategic actions to drive greater growth, innovation and performance.”